Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $32.96 billion. The enterprise value is $38.84 billion.
Market Cap | 32.96B |
Enterprise Value | 38.84B |
Important Dates
The next confirmed earnings date is Thursday, August 1, 2024, before market open.
Earnings Date | Aug 1, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Biogen has 145.60 million shares outstanding. The number of shares has increased by 0.48% in one year.
Shares Outstanding | 145.60M |
Shares Change (YoY) | +0.48% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.16% |
Owned by Institutions (%) | 93.01% |
Float | 145.09M |
Valuation Ratios
The trailing PE ratio is 28.26 and the forward PE ratio is 14.13. Biogen's PEG ratio is 6.24.
PE Ratio | 28.26 |
Forward PE | 14.13 |
PS Ratio | 3.41 |
Forward PS | 3.41 |
PB Ratio | 2.17 |
P/FCF Ratio | 25.66 |
PEG Ratio | 6.24 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.96, with an EV/FCF ratio of 30.24.
EV / Earnings | 33.29 |
EV / Sales | 4.02 |
EV / EBITDA | 20.96 |
EV / EBIT | 29.36 |
EV / FCF | 30.24 |
Financial Position
The company has a current ratio of 2.10, with a Debt / Equity ratio of 0.46.
Current Ratio | 2.10 |
Quick Ratio | 0.95 |
Debt / Equity | 0.46 |
Debt / EBITDA | 3.75 |
Debt / FCF | 5.41 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 7.90% and return on invested capital (ROIC) is 5.27%.
Return on Equity (ROE) | 7.90% |
Return on Assets (ROA) | 4.40% |
Return on Capital (ROIC) | 5.27% |
Revenue Per Employee | $1.28M |
Profits Per Employee | $154,108 |
Employee Count | 7,570 |
Asset Turnover | 0.36 |
Inventory Turnover | 1.27 |
Taxes
In the past 12 months, Biogen has paid $156.00 million in taxes.
Income Tax | 156.00M |
Effective Tax Rate | 11.79% |
Stock Price Statistics
The stock price has decreased by -18.23% in the last 52 weeks. The beta is -0.04, so Biogen's price volatility has been lower than the market average.
Beta (5Y) | -0.04 |
52-Week Price Change | -18.23% |
50-Day Moving Average | 226.90 |
200-Day Moving Average | 231.97 |
Relative Strength Index (RSI) | 49.15 |
Average Volume (20 Days) | 1,023,040 |
Short Selling Information
The latest short interest is 2.74 million, so 1.88% of the outstanding shares have been sold short.
Short Interest | 2.74M |
Short Previous Month | 3.07M |
Short % of Shares Out | 1.88% |
Short % of Float | 1.89% |
Short Ratio (days to cover) | 2.48 |
Income Statement
In the last 12 months, Biogen had revenue of $9.66 billion and earned $1.17 billion in profits. Earnings per share was $8.01.
Revenue | 9.66B |
Gross Profit | 7.25B |
Operating Income | 1.32B |
Pretax Income | 1.32B |
Net Income | 1.17B |
EBITDA | 1.85B |
EBIT | 1.32B |
Earnings Per Share (EPS) | $8.01 |
Balance Sheet
The company has $1.07 billion in cash and $6.95 billion in debt, giving a net cash position of -$5.87 billion or -$40.33 per share.
Cash & Cash Equivalents | 1.07B |
Total Debt | 6.95B |
Net Cash | -5.87B |
Net Cash Per Share | -$40.33 |
Equity (Book Value) | 15.21B |
Book Value Per Share | 104.49 |
Working Capital | 3.53B |
Cash Flow
In the last 12 months, operating cash flow was $1.65 billion and capital expenditures -$360.70 million, giving a free cash flow of $1.28 billion.
Operating Cash Flow | 1.65B |
Capital Expenditures | -360.70M |
Free Cash Flow | 1.28B |
FCF Per Share | $8.85 |
Margins
Gross margin is 75.03%, with operating and profit margins of 13.69% and 12.07%.
Gross Margin | 75.03% |
Operating Margin | 13.69% |
Pretax Margin | 13.69% |
Profit Margin | 12.07% |
EBITDA Margin | 19.17% |
EBIT Margin | 13.69% |
FCF Margin | 13.29% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.48% |
Shareholder Yield | -0.48% |
Earnings Yield | 3.54% |
FCF Yield | 3.90% |
Analyst Forecast
The average price target for Biogen is $286.26, which is 26.44% higher than the current price. The consensus rating is "Buy".
Price Target | $286.26 |
Price Target Difference | 26.44% |
Analyst Consensus | Buy |
Analyst Count | 23 |
Revenue Growth Forecast (5Y) | 2.14% |
EPS Growth Forecast (5Y) | 23.90% |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
Last Split Date | Jan 18, 2001 |
Split Type | Forward |
Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3.38 and a Piotroski F-Score of 4.
Altman Z-Score | 3.38 |
Piotroski F-Score | 4 |